Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer

Area of Science:

• Oncology
• Immunology

Background:

• Metastatic colorectal cancer (CRC) treatments have suboptimal outcomes.
• Advances in understanding the immune system's role in cancer have spurred new therapeutic strategies.
• Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, are key immunomodulatory agents.

Purpose of the Study:

• To review current and emerging data on PD-1/PD-L1 inhibitors in metastatic CRC.
• To analyze the efficacy of these inhibitors alone and in combination therapies.
• To discuss the challenges and future directions for immunotherapy in CRC.

Main Methods:

• Comprehensive review of early and late-phase clinical trials.
• Analysis of updated data on PD-1/PD-L1 inhibitors in various treatment combinations.
• Inclusion of data on microsatellite-instability-high (MSI-H) or mismatch repair-deficient (dMMR) CRC patient responses.

Main Results:

• PD-1/PD-L1 inhibitors offer a new therapeutic option for advanced CRC, particularly for MSI-H/dMMR subtypes.
• Some patients experience objective and sustained clinical responses to checkpoint inhibitors.
• Immunotherapy has had limited impact broadly but shows potential in specific patient populations.

Conclusions:

• PD-1/PD-L1 inhibitors represent a significant advancement in treating specific subsets of metastatic CRC.
• Combination therapies are under investigation to enhance treatment efficacy.
• Further research and ongoing trials are crucial to overcome challenges and optimize immunotherapy for CRC.